Orion Pharma (DHA:ORIONPHARM) Other Long-Term Liabilities: BDT597 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
74 GF Score
Price BDT28.80
GF Value BDT19.85
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Other Long-Term Liabilities?

Orion Pharma DHA:ORIONPHARM 74 Other Long-Term Liabilities is BDT597 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 74/100 and a GF Value™ of BDT19.85 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Orion Pharma's other long-term liabilities for the quarter that ended in Mar. 2026 was BDT597 Mil.

Orion Pharma's quarterly other long-term liabilities increased from Sep. 2025 (BDT562 Mil) to Dec. 2025 (BDT578 Mil) and increased from Dec. 2025 (BDT578 Mil) to Mar. 2026 (BDT597 Mil).

Orion Pharma's annual other long-term liabilities increased from Jun. 2023 (BDT301 Mil) to Jun. 2024 (BDT459 Mil) and increased from Jun. 2024 (BDT459 Mil) to Jun. 2025 (BDT546 Mil).

Orion Pharma Other Long-Term Liabilities Related Terms

Orion Pharma Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Other Long-Term Liabilities Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 281.69 265.65 301.10 458.84 545.53

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 523.26 545.53 562.23 578.08 596.66
DHA:ORIONPHARM
74GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of BDT597 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Other Long-Term Liabilities of BDT597 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's Other Long-Term Liabilities too high?
Orion Pharma's current Other Long-Term Liabilities is BDT597 Mil. Overall, Orion Pharma has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Other Long-Term Liabilities compare to CEG and VST?
Orion Pharma's Other Long-Term Liabilities of BDT597 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for an Utilities - Independent Power Producers company?
A good Other Long-Term Liabilities depends on the Utilities - Independent Power Producers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Orion Pharma and its competitors. Orion Pharma's current Other Long-Term Liabilities is BDT597 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT19.85, compared to a current price of BDT28.80 — trading 45.1% above its estimated fair value. The current Other Long-Term Liabilities is BDT597 Mil. Orion Pharma's overall GF Score™ is 74/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Other Long-Term Liabilities is BDT597 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT28.80 is trading 45.1% above its estimated GF Value™ of BDT19.85. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Other Long-Term Liabilities: BDT597 Mil
  • GF Value™: BDT19.85 vs. price of BDT28.80 (45.1% above fair value)
  • GF Score™: 74/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
74GF Score

Get the complete analysis for DHA:ORIONPHARM

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT28.80
Price
BDT19.85
GF Value